Tardive Dyskinesia and Type II Schizophrenia

1992 ◽  
Vol 160 (2) ◽  
pp. 253-256 ◽  
Author(s):  
Elizabeth J. B. Davis ◽  
Milind Borde ◽  
L. N. Sharma
Keyword(s):  
Cognitive Impairment ◽  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Thought Disorder ◽  
Control Group ◽  
Positive Symptoms ◽  
Type Ii ◽  
Formal Thought Disorder ◽  
Schizophrenic Patients ◽  
Male Patients

Cognitive impairment, negative and positive symptoms, primitive release reflexes, and age/temporal disorientation were assessed in 20 male patients meeting the DSM–III–R criteria for chronic schizophrenia and Schooler & Kane's criteria for TD. The control group comprised 20 age-matched male chronic schizophrenic patients without TD. Significant associations were found between TD, cognitive impairment, some negative symptoms, and formal thought disorder. These associations were independent of other illness and treatment variables. The severity of TD correlated significantly with that of cognitive impairment.

The Positive: Negative Dichotomy in Schizophrenia

1990 ◽  
Vol 157 (1) ◽  
pp. 41-49 ◽  
Author(s):  
A. M. Mortimer ◽  
C. E. Lund ◽  
P. J. McKenna
Keyword(s):  
Cognitive Impairment ◽  
Negative Symptom ◽  
Negative Symptoms ◽  
Thought Disorder ◽  
Motor Disorder ◽  
Positive Symptoms ◽  
Formal Thought Disorder ◽  
Symptom Scores ◽  
Schizophrenic Patients ◽  
Positive And Negative Symptoms

Two studies are reported. In the first, of 62 schizophrenic patients, no correlation between negative symptom scores (rated blindly) and any measure of positive symptoms was found. This independence was confirmed by factor and cluster analyses, which left the question of a third ‘disorganisation’ class of schizophrenic symptoms open. In the second study, of 80 patients, formal thought disorder separated unequivocally into ‘positive formal thought disorder’ and ‘alogia’ syndromes on the basis of correlations with positive and negative symptoms. Catatonic motor disorder also showed evidence of a corresponding positive: negative division, although this only emerged when severity or chronicity of illness was controlled for. Cognitive impairment showed a broad range of affiliations and its particular correlation with negative symptoms was perhaps artefactual.

Positive and Negative Symptoms in Psychiatry

1986 ◽  
Vol 148 (5) ◽  
pp. 587-589 ◽  
Author(s):  
Michael R. Trimble
Keyword(s):  
Negative Symptoms ◽  
Geographical Location ◽  
Personal Communication ◽  
Thought Disorder ◽  
Positive Symptom ◽  
Positive Symptoms ◽  
Market Research Company ◽  
Research Company ◽  
Schizophrenic Patients ◽  
Positive And Negative Symptoms

The terms positive and negative symptoms have slipped into the language of contemporary psychiatry with comparative ease. It is not uncommon for these expressions to be used with little explanation, both at meeting and in written communications, with the implicit understanding that their meaning is understood and that somehow they are of value to our knowledge of psychopathology. However, that there are no clear guide-lines at present for our use of these terms is shown from a recent survey of psychiatrists' opinions from a market research company (Martin Hamblin Research-Personal Communication). As part of a series of questions asked to many psychiatrists of differing age, geographical location, and status, they were asked about the meaning of these terms, positive and negative symptoms and the proportion of schizophrenic patients having them. Of the categories quoted by Crow (1980–81) as positive symptoms, 68% considered that delusions were positive symptoms, 63% hallucinations, and only 35% thought disorder. In contrast, 18% thought that behaviour disturbance was a positive symptom, a similar figure (15%) being given for passivity feelings. Considerable variation was noted, however, with hallucinations being considered positive by only 33% of London psychiatrists, thought disorder by only 11% of those qualified 16–25 years, and one-quarter of all registrars and psychiatrists from Midland Health Districts considered passivity feelings to fall into this category. Even greater disagreement was recorded for negative symptoms. Thus, the symptom most often associated with this category was apathy, by 52% of respondents. Only 26% considered that withdrawal was a negative symptom, the percentage data for lack of motivation and blunting of affect being 37% and 15% respectively.

Three Syndromes in Chronic Schizophrenia

1989 ◽  
Vol 155 (S7) ◽  
pp. 119-122 ◽  
Author(s):  
P.F. Liddle ◽  
Thomas R.E. Barnes ◽  
D. Morris ◽  
S. Haque
Keyword(s):  
Cognitive Impairment ◽  
Clinical Features ◽  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Brain Abnormalities ◽  
Brain Abnormality ◽  
Schizophrenic Patients ◽  
Extensive Body ◽  
Positive And Negative Symptoms

In recent years, exploration of the distinction between positive and negative symptoms of schizophrenia has provided a fruitful basis for attempts to relate the clinical features of schizophrenia to the accumulating evidence of brain abnormalities in schizophrenic patients. By 1982, there was an extensive body of evidence supporting the hypothesis that negative schizophrenic symptoms, such as poverty of speech and flatness of affect, were associated with substantial brain abnormalities, such as increased ventricular to brain ratio, and extensive cognitive impairment (Crow, 1980; Andreasen & Olsen, 1982). However, at that stage there were several fundamental unanswered questions about the nature of negative symptoms, and their relationship to indices of brain abnormality. This paper presents some findings of a series of studies initiated in 1982 to seek answers to some of these questions.

scholarly journals Cannabis use and abuse correlates in a homogenous South African schizophrenia population

2009 ◽  
Vol 15 (1) ◽  
pp. 5 ◽  
Author(s):  
Liezl Koen ◽  
Regan Jonathan ◽  
Dana JH Niehaus
Keyword(s):  
South African ◽  
Functional Outcomes ◽  
Negative Symptoms ◽  
Age Of Onset ◽  
Cannabis Use ◽  
Positive Symptoms ◽  
International Studies ◽  
Formal Thought Disorder ◽  
Schizophrenic Patients

<p><strong>Objective.</strong> Worldwide, cannabis is the most widely used illicit substance, and it has been identified as a correlate in schizophrenia samples for poorer symptomatic and functional outcomes in many international studies. The object of this retrospective study was to identify the prevalence of cannabis use/abuse and the demographic and clinical correlates therefor in a large homogeneous South African schizophrenia population.</p><p><strong>Methods.</strong> As part of a large genetic study, 547 subjects with a diagnosis of schizophrenia were recruited. Demographic and clinical data were collected and each participant underwent a urinary drug screen. Use/abuse of cannabis was defined as using cannabis more than 21 times in a single year. Subjects with and without cannabis use/abuse were statistically compared. <strong></strong></p><p><strong>Results.</strong> Significant differences between the two groups were found in terms of gender, marital status, age of onset of schizophrenia, number of hospitalisations and relapses, alcohol abuse, smoking, the Scale for the Assessment of Positive Symptoms (SAPS) scores for hallucinations, delusions, bizarre behaviour and formal thought disorder, and the Scale for the Assessment of Negative Symptoms (SANS) score for avolition/apathy. <strong></strong></p><p><strong>Conclusion.</strong> The prevalence of cannabis use/abuse in this study was high, and our findings were comparable with those of previous international studies. Abuse/use started mainly in the teenage years, was more prevalent among males than females, and was associated with negative overall outcomes. There was also a positive correlation between cannabis and nicotine and alcohol use/abuse. Determination of cannabis abuse based solely on history was found to be reliable, and urine cannabis testing appeared to be of limited value in routine management of this group of schizophrenic patients.</p>

The Assessment of Negative and Positive Features in Schizophrenia

1989 ◽  
Vol 155 (S7) ◽  
pp. 41-44 ◽  
Author(s):  
Eve C. Johnstone
Keyword(s):  
Negative Symptoms ◽  
Normal Function ◽  
Thought Disorder ◽  
List Type ◽  
Type Number ◽  
Formal Thought Disorder ◽  
Clinical Correlates ◽  
Schizophrenic Patients ◽  
The Relationship ◽  
Positive And Negative Symptoms

It has become customary to classify the typical abnormalities of the mental state of schizophrenic patients into positive and negative features, with reference to behavioural excesses and deficits. Positive features are pathological by their presence and negative features represent the loss of some normal function. Positive features are generally considered to include delusions, hallucinations and positive formal thought disorder (Fish, 1962). Some studies (e.g. Johnstone et al, 1978) have also included incongruity of affect under this heading. Negative features include affective flattening, poverty of speech, retardation, apathy, lack of sociability. There is some evidence that the clinical correlates of positive and negative features may not be the same (Owens & Johnstone, 1980). Some workers (Andreasen & Olsen, 1982) but not others (Pogue-Geile & Harrow, 1984) have found that among schizophrenic patients positive and negative symptoms were negatively correlated. Although the nature of the relationship between positive and negative features is not entirely established and may not be simple (Wing, 1978) certain generalisations may be applied: (a)Positive features are characteristic of earlier and negative of later phases of the illness (Pfohl & Winokur, 1982).(b)The effects of drugs upon positive features are greater than those upon negative features. Thus neuroleptics produce more marked improvement (Johnstone et al, 1978; Angrist et al, 1980) and amphetamine more marked exacerbation (Angrist et al, 1980) of positive than of negative features.(c)Positive features have been said to be relatively variable and negative features relatively stable (Ovchinnikov, 1968; Snezhnevsky, 1968).

scholarly journals Evaluation of paliperidone on social function in patients with chronic schizophrenia

2018 ◽  
Vol 31 (2) ◽  
pp. e000011
Author(s):  
Yan Gu ◽  
Hong Peng ◽  
Jingjing Dai ◽  
Hui Gao ◽  
Xianghong Yang ◽  
...  
Keyword(s):  
Interaction Effect ◽  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Social Function ◽  
Time Effect ◽  
Control Group ◽  
Positive Symptoms ◽  
Symptom Scale ◽  
Grouping Effect ◽  
The Difference

BackgroundThe impairment of social function is widespread in the patients with chronic schizophrenia, which seriously affects family, life and work conditions.AimsThe main purpose of this study was to investigate the efficacy of paliperidone in the treatment of social function in chronic schizophrenia.MethodsA total of 81 patients who met the standard criteria for schizophrenia and long-term hospitalised inpatients were randomly divided into the treatment group and normal control group following a 1- year prospective follow-up study. The reatment group (41 cases) used paliperidone extended-release tablets for reducing dosage, as appropriate, based on the original treatment strategy; and the control group (40 cases) used the former drugs. All patients were assessed using the Positive and Negative Symptom Scales (PANSS), and the Treatment Emergent Symptom Scale (TESS) was used to assess adverse drug reactions. The Hospitalised Psychiatric Patients’ Social Functions Rating Scale (SSPI) was used to assess social function of participants before and after 8  weeks, 6  months and 1 year of treatment.ResultsAt baseline there were no significant differences between the two groups in age, duration of illness, educational background and dosage of antipsychotic drugs (converted into chlorpromazine equivalency). There was statistically significant difference in PANSS positive symptoms by interaction effect (Fgroup×time=18.24, df=3237, p<0.001) and time effect (Ftime=21.66, df=3, p<0.01) and the difference in PANSS positive symptoms by grouping effect (Fgroup=0.68, df=1, p=0.41) was not statistically significant. The difference of grouping effect of PANSS negative symptoms (Fgroup=9.93, df=1, p=0.002), time effect (Ftime=279.15, df=3, p<0.001) and interaction effect (Fgroup×time=279.15, df=3237, p<0.001) were statistically significant. There were statistically significant differences in the grouping effect (Fgroup=6.59, df=1, p=0.012), time effect (Ftime=152.97, df=3, p<0.001) and interaction effect (Fgroup×time=148.82, df=3237, p<0.001) of PANSS general pathological symptoms, the same as the total score of the PANSS, which showed large differences in grouping effect (Fgroup=7.04, df=1, p=0.001), time effect (Ftime=210.78, df=3, p<0.001) and interaction effect (Fgroup×time=205.20, df=3237, p<0.01). We found in the total SSPI score, grouping effect (Fgroup=31.70, df=1, p<0.001), time effect (Ftime=161.84, df=3, p<0.001) and interaction effect (Fgroup×time=132.74, df=3237, p<0.001) were demonstrated to be significantly different. Even though adverse reactions occurred 7 times in the treatment group and 44 times in the control group based on the Treatment Emergent Symptom Scale (TESS), incidence rate was significantly lower than that of the control group (χ²=18.854, p<0.001).ConclusionPaliperidone can safely and effectively improve negative symptoms and social function in patients with chronic schizophrenia.

Two kinds of cognitive deficit associated with chronic schizophrenia

1977 ◽  
Vol 7 (1) ◽  
pp. 171-173 ◽  
Author(s):  
C. D. Frith
Keyword(s):  
Feature Selection ◽  
Negative Symptoms ◽  
Cognitive Deficit ◽  
Chronic Schizophrenia ◽  
Positive Symptoms ◽  
Chronic Schizophrenic ◽  
Normal Degree ◽  
Schizophrenic Patients

SynopsisThe performance of 21 chronic schizophrenic patients was investigated on two tests of feature selection. It was found that patients with negative symptoms (muteness, withdrawal, etc.) were characterized by an extreme lack of persistence, but selected usual features; whereas patients with positive symptoms (hallucinations, delusions, etc.) had a normal degree of persistence, but selected unusual features.

scholarly journals HIGH MOBILITY GROUP BOX-1 LEVELS IN SCHIZOPHRENIA: POTENTIAL BIOMARKER OF REMISSION PHASE

2020 ◽  
Author(s):  
Nuryil Yilmaz ◽  
Zekeriya Yelboga ◽  
Yavuz Yilmaz ◽  
Ozlem Demirpence
Keyword(s):  
Acute Exacerbation ◽  
Negative Symptoms ◽  
Rating Scale ◽  
High Mobility ◽  
High Mobility Group ◽  
Control Group ◽  
Positive Symptoms ◽  
Potential Biomarker ◽  
Schizophrenic Patients ◽  
Remission Phase

Background: Schizophrenia is a chronic mental disorder, characterized by acute exacerbation and remission phases. Immune system has a role in the pathophysiology of schizophrenia. High mobility group box-1 (HMGB-1)  is a macrophage secreted protein activating immune cells to produce cytokines. The aim of this study was to evaluate HMGB-1 levels among patients with schizophrenia both in acute exacerbation and remission phases. Methods: Consecutive schizophrenia patients in acute exacerbation and remission phases were enrolled and compared with each other and with age-sex matched healthy subjects. Patients were assessed with the Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms (SANS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Scale (CGI). Results: Mean HMGB-1 levels were not significantly different in acute exacerbation phase versus remission phase schizophrenia patients (2139±564 pg/ml vs. 2326±471 pg/ml, p=0.335) and both were individually higher than the control group (1791±444 pg/ml, p=0.05 for acute exacerbation vs control, p=0.002 for remission vs control). In remission phase schizophrenic patients, HMGB-1 levels were positively correlated with Scale For The Assessment of Positive Symptoms (r=0.447, p=0.015) and BPRS (r=0.397, p=0.033) scores and HMGB-1 levels were independently associated with BPRS. Conclusion: Serum HMGB-1 levels were shown to be increased in patients with schizophrenia patients irrespective of phase and HMGB-1 levels were related to symptom severity according to psychiatric scales among patients in remission phase of schizophrenia.  

scholarly journals Eye movement characteristics in male patients with deficit and non-deficit schizophrenia and their relationships with psychiatric symptoms and cognitive function

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Lin Zhang ◽  
Xiangrong Zhang ◽  
Xinyu Fang ◽  
Chao Zhou ◽  
Lu Wen ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Cognitive Function ◽  
Eye Movement ◽  
Negative Symptoms ◽  
Cognitive Test ◽  
Control Group ◽  
Deficit Schizophrenia ◽  
Movement Data ◽  
Movement Characteristics ◽  
Male Patients

Abstract Background The cognitive impairment pattern of deficit schizophrenia (DS) is centered on an impaired attention function. Previous studies have suggested that the exploratory eye movement (EEM) tests reflect attention deficits in patients with schizophrenia. However, no study has investigated the characteristics of eye movement in DS in the Chinese Han population. This study aimed to investigate the pattern of eye movement characteristics in DS patients and to examine whether eye movement characteristic is associated with serious negative symptoms and cognitive decline in this schizophrenia subtype. Methods A total of 86 male patients [37 DS and 49 non-deficit schizophrenia (NDS)] and 80 healthy controls (HC) participated in this study. Clinical symptoms were assessed using the Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS). Cognitive function was assessed using the Mattis Dementia Rating Scale (MDRS-2). Eye movement data of subjects were collected using an eye movement tracking analyzer. Results There were significant differences in the overall eye movement data and cognitive test scores among the three groups (all P < 0.001). Both DS and NDS schizophrenia subgroups showed more severe eye movement and cognitive impairment compared with the control group. The number of eye fixations (NEF), total of eye scanning length (TESL), and cognitive function in DS patients were significantly lower than those in NDS patients. The discriminant analysis (D score) was higher than that of the control group (P < 0.001). In the DS group, the inattention factor of SANS was negatively correlated with the attention factor (r = − 0.545, P = 0.001) and structure factor of cognitive (r = − 0.389, P = 0.023), the affective flattening factor of SANS was negatively correlated with TESL (r = − 0.353, P = 0.041) and initiation/retention factor of cognitive (r = − 0.376,P = 0.028). TESL was found to positively correlate with the MDRS-2 total score (r = 0.427, P = 0.012), attention factor (r = 0.354, P = 0.040), and memory factor (r = 0.349, P = 0.043) in the DS group, whereas the mean of eye scanning length (MESL) positively correlated with cognitive impairments in the NDS group. The negative symptoms showed no significant correlation with cognition in the NDS group. Conclusions Total of eye scanning length may be a characteristic eye movement symptom in DS patients, which is associated with serious negative symptoms and cognitive impairment in this schizophrenia subtype.

The Composition of the Negative Syndrome of Chronic Schizophrenia

1993 ◽  
Vol 162 (6) ◽  
pp. 744-750 ◽  
Author(s):  
D. A. Kibel ◽  
I. Laffont ◽  
P. F. Liddle
Keyword(s):  
Cognitive Impairment ◽  
Motor Activity ◽  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Depressive Illness ◽  
Interpersonal Interaction ◽  
Positive Symptoms ◽  
Moderate Correlation ◽  
Depressive Cognition ◽  
Negative Syndrome

The clinical features of patients who satisfy a variety of criteria for the negative syndrome can be arranged in five groups of phenomena: (a) poverty of thought and speech, (b) blunted affect, (c) decreased motor activity, (d) apathy and avolition, and (e) diminished interpersonal interaction. We have shown that depressed mood and depressive cognition are not related to the negative syndrome, but there is some overlap between the specific phenomena of depressive illness and negative symptoms in schizophrenia. Items measuring cognitive impairment have a moderate correlation with the negative syndrome, but the negative syndrome accounts for less than half of the variance of cognitive performance. These items that define the negative syndrome can be as reliably measured as depressive and positive symptoms.

Sign in / Sign up

Export Citation Format

Share Document